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ABSTRACT 62 
Impaired adipose tissue insulin signaling is a critical feature of insulin resistance. Here we 63 
identify a pathway linking the lipolytic enzyme, hormone-sensitive lipase (HSL), to insulin 64 
action via the glucose-responsive transcription factor ChREBP and its target, the fatty acid 65 
(FA) elongase, ELOVL6. Genetic inhibition of HSL in human adipocytes and mouse adipose 66 
tissue results in enhanced insulin sensitivity and induction of ELOVL6. ELOVL6 promotes an 67 
increase in phospholipid (PL) oleic acid which modifies plasma membrane fluidity and 68 
enhances insulin signaling. HSL deficiency-mediated effects are suppressed by gene silencing 69 
of ChREBP and ELOVL6. Mechanistically, physical interaction between HSL and 70 
ChREBPα, independently of lipase catalytic activity, impairs ChREBPα translocation into the 71 
nucleus and induction of ChREBPβ, the transcriptionally highly active isoform strongly 72 
associated to whole body insulin sensitivity. Targeting the HSL-ChREBP interaction may 73 
allow therapeutic strategies for the restoration of insulin sensitivity. 74 
  75 
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Introduction 76 
Insulin resistance is a pathogenic mechanism involved in a wide array of diseases. Besides the 77 
well-established early defect seen in type 2 diabetes, insulin resistance plays a role in the 78 
development of cancers such as colorectal cancer, liver diseases associated with non-alcoholic 79 
steatohepatitis, cardiovascular diseases or, reproductive dysfunction e.g., in polycystic ovary 80 
syndrome. Insulin resistance is also a feature of aging-related disorders such as 81 
neurodegenerative diseases e.g., in Alzheimer disease. Adipose tissue metabolism has 82 
emerged as a major determinant of systemic insulin sensitivity. Genetic ablation of insulin-83 
induced glucose transport in fat causes systemic insulin resistance 1. Direct manipulation of 84 
the fat cell insulin signaling pathway in mice also supports the systemic importance of 85 
adipose tissue 2-4. Defects in adipose insulin signaling have been reported in insulin resistant 86 
and type 2 diabetic patients 5-8. In this context, improvement of adipose tissue insulin action 87 
appears to be an important target for recovery of whole body systemic insulin sensitivity. 88 
Glitazones, a well-known class of insulin sensitizers, act through modulation of fat cell insulin 89 
sensitivity 9,10. Given their side-effects and subsequent withdrawal in many countries, there is 90 
an unmet need of drugs targeting adipose tissue. Excessive circulating levels of fatty acids are 91 
considered as important contributors to insulin resistance through development of fatty acid-92 
induced lipotoxicity in insulin-sensitive tissues such as liver and skeletal muscle 11. Lowering 93 
of plasma non-esterified fatty acid levels through inhibition of fat cell lipolysis has been 94 
proposed as an approach to improve insulin sensitivity. However, human data questions the 95 
association between production of fatty acids from adipose tissue lipolysis and insulin 96 
resistance in obesity 12. Partial deficiency in HSL (encoded by LIPE), one of the neutral 97 
lipases expressed in adipocytes, results in improvement of whole body insulin sensitivity in 98 
obese mice without changes in plasma fatty acid levels suggesting that other mechanisms than 99 
lipolysis are involved 13.  100 
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Here, in a series of in vitro and in vivo studies in humans and mice, we identified a pathway 101 
linking HSL to insulin resistance through interaction with the glucose-responsive transcription 102 
factor ChREBP. The physical interaction between HSL and ChREBP impairs nuclear 103 
translocation and activity of the transcription factor. In fat cells, the lipogenic enzyme 104 
ELOVL6 is a preferential target of ChREBP. Inhibition of HSL promotes activity of ELOVL6 105 
and enhances insulin signaling through enrichment of plasma membrane phospholipids in 106 
oleic acid. 107 
 108 
Reduction in HSL expression promotes de novo lipogenesis and insulin signaling in 109 
human adipocytes  110 
In adipocytes differentiated from human multipotent adipose-derived stem (hMADS) cells 111 
14,15, HSL gene silencing (Supplementary Fig. 1a,b,c) increased insulin-stimulated glucose 112 
transport (Fig. 1a), glucose oxidation (Fig. 1b) and glucose carbon incorporation into FA, i.e. 113 
de novo lipogenesis (Fig. 1c). Insulin signaling was enhanced in adipocytes with decreased 114 
HSL expression as shown by enhanced activating phosphorylations of insulin receptor 115 
substrate 1 (IRS1-pY612) and V-Akt murine thymoma viral oncogene homolog 116 
(AKT)/protein kinase B (AKT-pS473, AKT-pT308) after insulin treatment (Fig. 1d,e,f). 117 
Phosphorylation of AS160, an AKT substrate regulating translocation of the insulin-sensitive 118 
glucose transporter GLUT4, showed a trend similar to IRS1 and AKT phosphorylation (Fig. 119 
1g). As adipose tissue de novo lipogenesis is associated with insulin sensitivity in humans 120 
16,17, we tested whether direct inhibition of de novo lipogenesis has an impact on the 121 
modulation of insulin signaling induced by HSL depletion. To this end, human adipocytes 122 
were treated with a selective inhibitor of FA synthase, the rate-limiting enzyme in the 123 
synthesis of palmitic acid (Supplementary Fig. 1d). The FA synthase inhibitor blunted the 124 
induction of insulin-mediated phosphorylation of AKT observed in HSL-deficient fat cells 125 
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(Supplementary Fig. 1e). To further probe the role of de novo lipogenesis, we analyzed FA 126 
composition in fat cell triglycerides (TG) and PL. HSL inhibition significantly decreased the 127 
proportion of palmitic acid and palmitoleic acid but increased that of oleic acid in TG and PL 128 
(Fig. 1h,i). 129 
To define the molecular mechanisms underlying the changes in FA composition, we analyzed 130 
gene expression of enzymes catalyzing key steps in the synthesis of the main saturated and 131 
monounsaturated FA derived from glucose in human fat cells (Supplementary Fig. 1d). In 132 
hMADS adipocytes with decreased HSL expression, the most robust induction was observed 133 
for ELOVL6 (Fig. 1j). The increase in ELOVL6 mRNA level was mirrored by an increase in 134 
enzyme activity (Supplementary Fig. 1f) and an increase in the FA elongation ratio 135 
attributable to ELOVL6 activity (Supplementary Fig. 1g). To confirm data from hMADS 136 
adipocytes, we performed HSL gene silencing in human preadipocytes differentiated in 137 
primary cultures. ELOVL6 also showed the highest induction among de novo lipogenesis 138 
genes (Supplementary Fig. 1h). Next, we evaluated the effect of adipose triglyceride lipase 139 
(ATGL encoded by PNPLA2), through ATGL gene silencing in hMADS adipocytes 140 
(Supplementary Fig. 1i,j). ATGL precedes HSL in the sequential breakdown of TG during 141 
adipocyte lipolysis. Contrarily to what is observed during HSL depletion, ATGL knock down 142 
had no effect on ELOVL6 and other de novo lipogenic enzyme mRNA levels as well as on the 143 
FA elongation ratio attributable to ELOVL6 activity (Supplementary Fig. 1k,l). Altogether, 144 
the results show that HSL depletion improves insulin signaling and, promotes de novo 145 
lipogenesis and modification in FA composition. These changes are associated with induction 146 
of the FA elongase ELOVL6. 147 
 148 
HSL inhibition is associated with improved insulin sensitivity and increased adipose 149 
tissue Elovl6 expression in vivo 150 
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To probe changes in insulin sensitivity upon decreased HSL expression in vivo, we 151 
investigated different mouse transgenic models, genetic backgrounds and diets. First, we 152 
investigated B6D2/F1 transgenic mice with Lipe haploinsufficiency fed with 60% high fat 153 
diet 13. Compared to obese wild type littermates, the mice showed no differences in body 154 
weight and fat mass (Supplementary Fig. 2a,b). During euglycemic hyperinsulinemic clamp, 155 
the glucose infusion rate tended to increase (Fig. 2a) while there was no change in glucose 156 
rate of disappearance in obese Lipe haploinsufficient mice compared with wild type 157 
littermates (Fig. 2b). Insulin-mediated suppression of hepatic glucose production was 158 
improved (Fig. 2c). In a second cohort of B6D2/F1 mice fed 45% high fat diet, insulin 159 
tolerance was improved while body weight was not modified in Lipe haploinsufficient mice 160 
compared with wild type littermates (Fig. 2d, Supplementary Fig. 2c). In a third cohort of 161 
C57BL/6J mice fed 60% high fat diet, we confirmed enhanced insulin sensitivity in Lipe 162 
haploinsufficient mice as determined by quantitative insulin-sensitivity check index 163 
(QUICKI) (Fig. 2e). Adipose Elovl6 gene expression was higher in mice with diminished 164 
HSL expression (Fig. 2f). As in human adipocytes (Fig. 1j, Supplementary Fig 1h), the 165 
induction was more pronounced for Elovl6 than for other lipogenic genes (Supplementary 166 
Fig. 2d). 167 
To generate a mouse model with HSL knock down in adipose tissue and unaltered expression 168 
in liver, we produced B6D2/F1 mice with zinc finger nuclease-mediated deletion of exon B 169 
(Supplementary Fig. 2e). The promoter upstream of exon B governs HSL expression in fat 170 
cells 18. LipeexonB-/- mice showed decreased expression of HSL in adipose tissue (Fig. 2g,h). In 171 
liver, the low levels of HSL which are mainly composed of exon A-containing transcripts, 172 
were not modified (Supplementary Fig. 2f,g). LipeexonB-/- mice fed high fat diet showed 173 
improved glucose tolerance (Fig. 2i) without alteration of body weight (Supplementary Fig. 174 
2h). Adipose Elovl6 gene expression was higher in these mice compared to wild type 175 
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littermates (Fig. 2j). Pharmacological inhibition of HSL had positive effect in C57BL/6J 176 
mice. Chronic treatment with a specific inhibitor of HSL did not alter body weight 177 
(Supplementary Fig. 2i) but resulted in increased QUICKI (Supplementary Fig. 2j) and 178 
higher induction of adipose Elovl6 gene expression (Supplementary Fig. 2k). Therefore, 179 
both genetic and pharmacologic inhibition of HSL results in improved insulin sensitivity and 180 
enhanced Elovl6 expression in adipose tissue in vivo. 181 
 182 
Adipose ELOVL6 has a positive effect on insulin signaling and is associated with insulin 183 
sensitivity in vitro and in vivo 184 
To determine whether ELOVL6 was involved in the improvement of insulin signaling when 185 
fat cell HSL expression is diminished, we performed siRNA-mediated knockdown of 186 
ELOVL6 in human adipocytes. Gene silencing led to a significant decrease in ELOVL6 187 
mRNA level and activity (Supplementary Fig. 3a,b). The increases in IRS1 (Fig. 3a) and 188 
AKT (Fig. 3b, Supplementary Fig. 3c) phosphorylation observed in HSL-deficient 189 
adipocytes were abrogated following concomitant gene silencing of ELOVL6. To assess the 190 
importance of Elovl6 on adipose tissue insulin signaling in vivo, a bolus of insulin was 191 
injected to wild type and Elovl6 null mice of similar body weights prior to collection and 192 
analyses of fat pads (Supplementary Fig. 3d,e). In agreement with in vitro data in human 193 
adipocytes, insulin-stimulated Akt phosphorylation was decreased in adipose tissue of Elovl6 194 
null mice (Fig. 3c). These results reveal a strong link between ELOVL6 and insulin signaling 195 
in fat cells and identify ELOVL6 as the mediator of the beneficial effects of HSL inhibition. 196 
The relationship between adipose tissue ELOVL6 and insulin sensitivity was further explored 197 
in mouse models and clinical cohorts. In mice fed high fat diet, the C57BL/6J strain showed 198 
higher insulin tolerance than DBA/2J strain (Fig. 3d, Supplementary Fig. 3f). The better 199 
insulin action in C57BL/6J mice was accompanied by higher induction of adipose tissue 200 
Elovl6 gene expression during refeeding (Fig. 3e). In humans, ELOVL6 gene expression was 201 
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first measured in visceral adipose tissue from lean insulin-sensitive individuals and obese 202 
patients with metabolic syndrome, the latter being characterized by higher body mass index 203 
and lower glucose disposal rate measured during euglycemic hyperinsulinemic clamp (Fig. 3f, 204 
Supplementary Fig. 3g). Adipose tissue ELOVL6 mRNA levels were lower in insulin 205 
resistant individuals (Fig. 3g). Additional evidence was provided by a longitudinal study. In 206 
morbidly obese subjects, the weight loss observed two years after bariatric surgery 207 
(Supplementary Fig. 3h) was associated with an improvement in insulin sensitivity 208 
estimated by euglycemic hyperinsulinemic clamp-derived M value (Fig. 3h) and an increase 209 
in subcutaneous adipose ELOVL6 mRNA level (Fig. 3i). A strong positive correlation was 210 
found between ELOVL6 mRNA levels in subcutaneous fat and M value (Supplementary Fig. 211 
3i). Taken together, both murine and human data show a positive association between adipose 212 
ELOVL6 expression and insulin sensitivity in vivo. 213 
 214 
ELOVL6 positive effect on insulin signaling is mediated by oleic acid content in PL and 215 
plasma membrane fluidity 216 
We sought to identify the mechanisms by which ELOVL6 improves insulin signaling. 217 
Considering that the enzyme catalyzes critical steps in FA synthesis (Supplementary Fig. 218 
1d), we investigated the direct contribution of ELOVL6 on the changes in fat cell FA 219 
composition. In TG (Fig. 4a) and PL (Fig. 4b) of human adipocytes, diminished ELOVL6 220 
expression led to an increase in palmitic acid and palmitoleic acid at the expense of oleic acid. 221 
Analyses of these FAs were then performed on each class of PL. ELOVL6-deficient 222 
adipocytes showed a decrease in the proportion of oleic acid (e.g., 36:2) and an increase in the 223 
proportion of palmitic acid (e.g., 32:0) and palmitoleic acid (e.g., 32:2) in 224 
phosphatidylcholines and phosphatidylethanolamines (Supplementary Fig. 4a-d). In 225 
phosphatidylinositides, there was a decrease in 36:2 whereas no change was observed for 226 
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phosphatidylserines. These findings were in agreement with in vivo data, where the lack of 227 
Elovl6 in mouse adipose tissue resulted in increased palmitic and palmitoleic acid and 228 
decreased oleic acid contents in adipose tissue (Supplementary Fig. 4e). The changes in FA 229 
composition of PL suggest potential modification in plasma membrane properties. As 230 
ELOVL6 mediates the positive effect of HSL gene silencing on insulin signaling (Fig. 3a,b, 231 
Supplementary Fig. 3c), we determined whether this effect was dependent on oleic acid. 232 
There are two enzymatic steps between palmitic acid and oleic acid (Supplementary Fig. 233 
1d). The first is the elongation of palmitic acid into stearic acid catalyzed by ELOVL6 and the 234 
second is the desaturation of stearic acid into oleic acid catalyzed by SCD, a highly active 235 
process in fat cells 19-22. To investigate the respective contribution of the two steps, specific 236 
inhibitors were used. Treatment of human adipocytes with an inhibitor of ELOVL6 23 resulted 237 
in the expected changes in FA composition with a decrease of the C18/C16 FA ratio (Fig. 4c). 238 
Concordant with data obtained using gene silencing (Fig. 3b), pharmacological inhibition of 239 
ELOVL6 abrogated the enhancement of insulin-induced AKT phosphorylation observed in 240 
HSL-deficient adipocytes (Fig. 4d). A specific SCD inhibitor 24 decreased C16 and C18 FA 241 
desaturation (Fig. 4e) and had the same effect as the ELOVL6 inhibitor on AKT 242 
phosphorylation (Fig. 4f). Our data suggest that SCD is necessary but does not play a rate-243 
limiting role as does ELOVL6 in the improvement of insulin signaling induced by HSL 244 
inhibition. Accordingly, SCD mRNA levels are much higher than ELOVL6 mRNA levels in 245 
human adipocytes (Supplementary Fig. 4f). In additional experiments, the content of oleic 246 
acid in PL was directly modified by incubation of adipocytes with the FA (Fig. 4g). Exposure 247 
of HSL and ELOVL6 double deficient adipocytes to oleic acid rescued insulin-induced AKT 248 
phosphorylation to levels comparable with that observed in fat cells with diminished HSL 249 
expression (Fig. 4h). Therefore, the beneficial role of ELOVL6 on insulin signaling in human 250 
adipocytes is mediated by modulation of oleic acid content. 251 
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The composition of FA in PL may influence insulin signal transduction through modification 252 
of plasma membrane properties 19,25,26. To determine the consequence of ELOVL6-mediated 253 
changes in PL FA composition on plasma membrane fluidity, overexpression of ELOVL6 in 254 
human adipocytes was achieved using an adenoviral vector (Supplementary Fig. 4g,h). The 255 
resulting increase in C18/C16 FA ratio (Fig. 4i) was associated with an increase in insulin-256 
induced IRS1 phosphorylation (Fig. 4j). Fluorescence recovery after photobleaching (FRAP) 257 
data were analyzed in cells overexpressing ELOVL6 which plasma membrane glycolipids 258 
were labeled by fluorescent cholera toxin subunit B (Fig. 4k). Comparison of the mobile 259 
fractions (Fig. 4l) revealed an increase in plasma membrane lateral mobility of cholera toxin-260 
bound glycolipids in ELOVL6-overexpressing adipocytes. Collectively, the data suggest that 261 
enhanced adipocyte ELOVL6 activity increases the proportion of oleic acid in PL and 262 
positively influences insulin signaling through modulation of plasma membrane fluidity. 263 
 264 
The glucose-responsive transcription factor ChREBP mediates the beneficial effect of 265 
diminished HSL expression through ELOVL6 induction 266 
ELOVL6 is a direct transcriptional target of ChREBP 27. Adipose ChREBP is a major 267 
determinant of systemic insulin action on glucose metabolism 28. Therefore, the direct 268 
contribution of ChREBP to HSL gene silencing-mediated improvement of glucose 269 
metabolism in human adipocytes was evaluated using RNA interference (Supplementary 270 
Fig. 5a). During dual knockdown of HSL and ChREBP, the beneficial effects on glucose 271 
metabolism observed in adipocytes with low HSL expression were diminished. Glucose 272 
transport was decreased to control levels and the induction of de novo lipogenesis observed in 273 
cells with single HSL knockdown was lowered in adipocytes with dual knockdown of HSL 274 
and ChREBP (Fig. 5a,b). A similar pattern was observed for glucose and acetate carbon 275 
incorporation into FA (Fig. 5b,c) showing that the upregulation of FA synthesis resulted not 276 
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only from increased glucose uptake but also from specific induction of de novo lipogenesis. 277 
ChREBP gene silencing also mitigated the increase in insulin-induced IRS1 and AKT 278 
phosphorylation (Fig. 5d,e). These results indicate that ChREBP is involved in the 279 
improvement of glucose metabolism and insulin signaling induced by HSL downregulation. 280 
Similarly to what had been observed for ELOVL6 knock down (Fig. 4a,b), ChREBP gene 281 
silencing led to an increase in palmitic acid and palmitoleic acid and a decrease of oleic acid 282 
(Fig. 5f,g). Accordingly, ChREBP gene silencing potently suppressed ELOVL6 gene 283 
expression but had weak or no effect on other lipogenic genes suggesting that ELOVL6 is a 284 
preferential target of ChREBP in human fat cells (Fig. 5h). The involvement of ChREBP in 285 
adipose Elovl6 gene expression was confirmed in vivo. In adipose tissue of Mlxipl null mice 286 
(Supplementary Fig. 5b), Elovl6 was the lipogenic gene which expression was the most 287 
severely impaired (Fig. 5i). 288 
Two isoforms of ChREBP have been identified. ChREBPα, which transcriptional activity is 289 
regulated by glucose, and ChREBPβ, a transcriptionally superactive and unstable isoform 290 
which is a direct transcriptional target of ChREBPα 28,29. We characterized the human β-291 
specific exon of MLXIPL which extends 29 deoxynucleotides 3’ of its mouse counterpart 28 292 
(Supplementary Fig. 5c). In human adipocytes with siRNA-mediated knock down of HSL, 293 
the levels of ChREBP transcripts, notably the β isoform, were increased (Fig. 5j). 294 
Recruitment of ChREBP on the functional carbohydrate response element (ChoRE) in the 295 
ELOVL6 promoter was investigated using chromatin immunoprecipitation assays 27. In 296 
hMADS adipocytes, more binding events were detected on the ELOVL6 ChoRE than on 297 
positive control regions in RORC and TXNIP, a well characterized target of ChREBP 298 
(Supplementary Fig. 5d). ChREBP recruitment onto the ELOVL6 promoter was markedly 299 
enhanced in HSL-deficient compared to control adipocytes (Fig. 5k). 300 
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Interestingly, ELOVL6 was strongly associated with ChREBPβ gene expression in human 301 
hMADS adipocytes (Fig. 5l) and human differentiated primary preadipocytes 302 
(Supplementary Fig. 5e). Albeit less potent, a positive correlation was also found between 303 
ELOVL6 and ChREBPα (Supplementary Fig. 5f). Similarly, a highly significant correlation 304 
between ELOVL6 and ChREBPβ was observed in human subcutaneous adipose tissue 305 
samples (Fig. 5m). Short term elevation in plasma glucose and insulin levels during a 306 
hyperglycemic hyperinsulinemic clamp led to a pronounced induction of adipose ChREBPβ 307 
(Fig. 5n) and ELOVL6 (Fig. 5o) gene expression, illustrating the importance of glucose flux 308 
into the fat cells in the control of ELOVL6 expression in humans. Altogether, our results show 309 
that ChREBPβ mediates the effect of HSL deficiency on glucose metabolism and insulin 310 
signaling through transcriptional activation of ELOVL6. 311 
 312 
HSL modifies ChREBP activity in fat cells through protein-protein interaction 313 
As HSL catalyzes one of the rate-limiting steps in fat cell TG hydrolysis, we investigated 314 
whether lipolysis per se contributed to the induction of ChREBP. Several lines of evidence 315 
suggest that this is not the case. In the culture conditions used to study de novo lipogenesis, 316 
the release of glycerol and FA in the culture medium was low and was not influenced by HSL 317 
gene silencing (Supplementary Fig. 6a,b). Adipocytes were then treated with triacsin C, a 318 
potent inhibitor of long chain fatty acyl CoA synthetase 14. If FAs were involved, enhanced 319 
FA levels due to blockade of FA re-esterification should influence ChREBP and ELOVL6 320 
induction in adipocytes with HSL knock down. However, the upregulation of ChREBP 321 
isoform and ELOVL6 mRNA was not influenced by the treatment (Supplementary Fig. 6c-322 
e). These data show that the lipolytic activity of HSL does not contribute to the induction of 323 
ChREBP. 324 
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These findings led us to hypothesize that physical interaction between HSL and ChREBP may 325 
influence ChREBP activity. HEK293 cells were transfected with vectors expressing HSL and 326 
ChREBPα with FLAG epitope tag 30. Immunoprecipitation of cell lysates with anti-FLAG 327 
IgG and immunoblotting with anti-HSL antibody showed that HSL co-immunoprecipitated 328 
with ChREBPα (Supplementary Fig. 6f). Co-immunoprecipitation was observed using 329 
FLAG-ChREBP immobilized on magnetic beads and recombinant HSL (Fig. 6a). Surface 330 
plasmon resonance assays supported a direct binding between ChREBPα and HSL (Fig. 6b). 331 
Interaction between endogenous proteins in adipocytes was shown through 332 
immunoprecipitation with anti-ChREBP and anti-HSL antibodies (Fig. 6c, Supplementary 333 
Fig. 6g). In line with the lack of effect on de novo lipogenesis (Supplementary Fig. 1k,l), 334 
ATGL displayed no interaction with ChREBPα further indicating that HSL interaction with 335 
ChREBPα is independent lipolysis and specific to this neutral lipase (Fig. 6c).  336 
Furthermore, interaction of HSL with ChREBPα was shown using in situ proximity ligation 337 
assays using a pair of primary antibodies raised in two different species and a pair of 338 
secondary antibodies coupled to oligodeoxynucleotides 31. Specific and robust fluorescence 339 
signals were observed in the cytosol of fat cells from subcutaneous adipose tissue 340 
(Supplementary Fig. 6h). Such signals were also seen in differentiated hMADS adipocytes 341 
(Supplementary Fig. 6i). Little signal was detected in undifferentiated fibroblasts which do 342 
not express HSL. Negative controls using incomplete sets of antibodies and assays using anti-343 
ATGL and anti-AKT combined with anti-ChREBP antibodies supported specificity of the 344 
interaction (Supplementary Fig. 6j,k). Human HepG2 hepatocytes which express significant 345 
level of ChREBP but minute amounts of HSL showed few fluorescent spots (Supplementary 346 
Fig. 6l,m). Respective expression of ChREBPα and HSL in mouse tissues is coherent with a 347 
fat-specific interaction of the two proteins (Supplementary Fig. 6n). The data suggest that 348 
ChREBPα interaction with HSL is specific to fat cells. 349 
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In mouse adipose tissue, co-immunoprecipitation between HSL and ChREBP was diminished 350 
in Lipe haploinsufficient mice (Fig. 6d). In human adipocytes, HSL binding to ChREBPα was 351 
reduced in cytoplasm when HSL expression was diminished using siRNA (Fig. 6e, 352 
Supplementary Fig. 7a). This resulted in modification of ChREBP cellular distribution. 353 
Compared to control cells, adipocytes with low HSL expression showed higher 354 
immunofluorescence of ChREBP in nuclei indicating that ChREBPα nuclear translocation is 355 
facilitated when interaction with HSL is diminished (Fig. 6f). Subcellular fractionation 356 
confirmed an increased nuclear translocation in human adipocytes and mouse adipose tissues 357 
with low HSL expression whereas no significant differences was observed in the cytosolic 358 
fraction (Fig. 6g,h, Supplementary Fig. 7b,c). In mice, there was no difference in ChREBPα 359 
protein content in fat pads of the two genotypes (Supplementary Fig. 7d). To evaluate the 360 
effect of HSL on ChREBPα transcriptional activity, HEK293 cells were transfected with a 361 
vector containing the luciferase reporter gene under the control of a promoter containing 362 
functional ChoREs 32. Promoter activity increased when cells expressed ChREBPα and 363 
decreased when cells co-expressed increasing amounts of HSL (Fig. 6i, Supplementary Fig. 364 
7e). The data suggest that HSL binds to ChREBPα and sequesters the transcription factor in 365 
the cytoplasm. Upon decrease of HSL expression, HSL-ChREBP interaction is diminished, 366 
ChREBPα nuclear translocation is facilitated and its transcriptional activity is enhanced as 367 
shown here in reporter gene assays and above in chromatin immunoprecipitation analysis 368 
(Fig. 5k). 369 
When HEK293 cells expressing HSL and ChREBP were treated with a HSL inhibitor, less 370 
interaction between HSL and ChREBP was observed (Supplementary Fig. 7f). In human 371 
adipose tissue, we previously identified a short form of HSL produced by in-frame skipping 372 
of exon 6 (Supplementary Fig. 2e) 33,34. As exon 6 encodes the catalytic site Serine, HSL 373 
short form is devoid of enzymatic activity (Supplementary Fig. 7g). Expressed in HEK293 374 
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cells, HSL short form retained the capacity to bind ChREBP (Fig. 6j). An adenovirus 375 
expressing HSL short form was used to transduce human adipocytes transfected with control 376 
or LIPE siRNA (Supplementary Fig. 7h). The induction of ELOVL6 in adipocytes with 377 
diminished levels of HSL was blunted when HSL short form was expressed (Fig. 6k). A 378 
similar pattern was observed for other de novo lipogenesis gene expression (Supplementary 379 
Fig. 7i). The catalytically inactive form also reduced the increase in IRS1 phosphorylation 380 
mediated by HSL down regulation (Fig. 6l). Of note, the improvement of fat cell insulin 381 
signaling was observed with no change in amount of ChREBPα protein in adipocytes 382 
expressing HSL-S and in the absence of correlation between HSL and ChREBPα levels. 383 
(Supplementary Fig. 7j,k). Altogether, our data suggest that HSL plays an important role 384 
besides the hydrolysis of lipids in fat cells, the repression of ChREBP activity via direct 385 
interaction with the transcription factor (Supplementary Fig. 8). 386 
 387 
Discussion 388 
Considering the soaring incidence of diseases characterized by an insulin resistance state, 389 
there is a lack of drugs acting on adipose tissue. Its specialized cells, the adipocytes, have 390 
great potential to be therapeutically targeted 35. Partial inhibition of the fat cell neutral lipase, 391 
HSL, alleviates insulin resistance without increasing body weight, two essential requirements 392 
for therapeutic interventions 13 (and present work). Evolution of plasma fatty acid level and 393 
variation in insulin sensitivity was dissociated in this model. Here, we deciphered the 394 
mechanisms behind HSL inhibition-mediated improvement of glucose metabolism and 395 
identified interactions between prototypical metabolic pathways of the adipocyte. We show 396 
that, independently of lipolysis and the enzyme catalytic activity, HSL physically interacts 397 
with and inhibits the transcription factor ChREBP. ChREBP controls the FA elongase 398 
ELOVL6 catalyzing a limiting step in oleic acid synthesis. The resulting increase in PL oleic 399 
acid content modifies plasma membrane properties and improves insulin signaling.  400 
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Adipose de novo lipogenesis is positively associated with systemic insulin sensitivity 36,37. De 401 
novo lipogenesis is under the control of the glucose-responsive transcription factor, ChREBP. 402 
A positive association between insulin sensitivity and adipose ChREBP, notably, the 403 
transcriptionally superactive β isoform, has been reported 16,28,38. In human adipocytes, we 404 
show that knockdown of ChREBP counteracts the beneficial effects of HSL gene silencing on 405 
insulin sensitivity. We identify the FA elongase ELOVL6 as the main target of ChREBPβ in 406 
HSL-deficient adipocytes. In humans, ELOVL6 expression in fat was lower in insulin resistant 407 
than in insulin sensitive subjects in line with previous reports 16,39. Of note, in monozygotic 408 
twin pairs discordant for type 2 diabetes, adipose ELOVL6 is markedly lower in the affected 409 
twins 40. Our results from bariatric surgery, a longitudinal intervention improving insulin 410 
control of glucose metabolism, also supported the tight link between adipose ELOVL6 and 411 
insulin sensitivity.  412 
ELOVL6 catalyzes a critical step in the elongation of C16 FA 22,41. In adipocytes, enhanced 413 
ELOVL6 activity favored oleic acid synthesis while ELOVL6 knock down had the opposite 414 
effect. Diets rich in olive oil improve insulin sensitivity at adipocyte and whole-body levels 415 
42,43. This effect may contribute to the decreased incidence of type 2 diabetes in patients at risk 416 
fed Mediterranean diets 43. At the cellular level, monounsaturated fatty acids have been 417 
reported to protect from the damaging effect of palmitic acid on insulin signaling 19,26. As 418 
ELOVL6 induced an increase of oleic acid in major classes of PL, we postulated that it may 419 
alter plasma membrane fluidity owing to its conformational plasticity 25,44,45. The plasma 420 
membrane lateral mobility of glycolipids was increased in fat cells overexpressing ELOVL6. 421 
We therefore propose that ELOVL6-mediated increase in PL oleic acid content improves fat 422 
cell insulin signaling through alteration of plasma membrane properties. In mice, Elovl6 423 
deficiency impaired white adipose tissue insulin signaling whereas the opposite or lack of 424 
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alteration have previously been reported in the liver suggesting tissue-specific differences in 425 
ELOVL6-mediated modulation of insulin action 41,46. 426 
The role of HSL in human fat cell lipolysis is well established 14,47. HSL is a multifunctional 427 
enzyme with a broad range of substrates. Besides tri-, di- and monoglycerides, HSL is able to 428 
hydrolyze other esters, such as cholesteryl and retinyl esters 48. As ChREBP activity is 429 
influenced by metabolites and other transcription factors in liver, it could be postulated that 430 
products of HSL enzymatic activity directly or indirectly influence ChREBP-mediated 431 
modulation of gene transcription 29. However, although we cannot rule out that, in some 432 
conditions, upregulation of ChREBPα protein expression partially contributes to the 433 
phenotype of adipocytes depleted in HSL, we bring a solid body of evidence that physical 434 
interaction between HSL and ChREBPα controls the intracellular location and activity of the 435 
transcription factor in fat cells. ATGL which catalyzes the first step in adipose tissue lipolysis 436 
does not interact with ChREBP and does not modulate de novo lipogenesis gene expression. 437 
Moreover, using a short inactive form of HSL lacking the catalytic site Serine, we could show 438 
that the catalytic activity of HSL is dispensable for the interaction with ChREBP and 439 
ChREBP-mediated effect on ELOVL6 expression and insulin signaling. Noteworthy, our data 440 
provide a function to this naturally occurring form expressed in human adipose tissue 33. A 441 
specific HSL inhibitor was able to diminish the interaction between HSL and ChREBP and 442 
enhance adipose Elovl6 expression in mice. It may be hypothesized that the inhibitor binding 443 
to the catalytic pocket induces conformational change partially disrupting HSL-ChREBP 444 
interaction. The data suggest that small molecules may be designed and used to disrupt the 445 
interaction. Reducing the interaction between HSL and ChREBP favors ChREBP nuclear 446 
translocation and its transcriptional activity. This pathway provides a molecular basis to the 447 
differential control of de novo lipogenesis in liver and adipose tissue. ChREBP is involved in 448 
the regulation of de novo lipogenesis in the two tissues 29,49. However, the pathway is 449 
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generally considered as detrimental in the liver as it is activated during the development of 450 
fatty liver disease whereas it is seen as beneficial in adipose tissue as the link with insulin 451 
sensitivity has been shown both in clinical studies and in mouse models 50.  HSL is expressed 452 
at much higher level in fat cells than in hepatocytes. Accordingly, interaction between HSL 453 
and ChREBP is not found in human hepatocytes. Alleviation of HSL-mediated inhibition of 454 
ChREBP activity may constitute a fat cell-specific mechanism to enhance de novo lipogenesis 455 
and insulin signaling. 456 
To conclude, our work identifies a pathway critical for optimal insulin signaling in fat cells 457 
which links the neutral lipase HSL to the glucose-responsive transcription factor ChREBP and 458 
its target gene, the FA elongase, ELOVL6. This constitutes a unique example of an enzyme 459 
involved in lipid metabolism which independently of its enzymatic activity inhibits the 460 
transcriptional activity of a glucose-responsive transcription factor through protein-protein 461 
interaction. Inhibition of the HSL-ChREBP interaction may constitute an adipose-specific 462 
strategy to reduce insulin resistance. 463 
  464 
Morigny, Houssier et al.  21 
ACKNOWLEDGMENTS 465 
The authors gratefully acknowledge Dr. Nicolas Venteclef (Centre de Recherche des 466 
Cordeliers, Paris, France) and Dr. Jérémie Boucher (AstraZeneca, Göteborg, Sweden) for 467 
critical reading and comments on the manuscript. Emilie Courty and Jean Personnaz 468 
participated in mouse studies during internship at I2MC. The GenoToul Animal Care, 469 
Anexplo, Imaging-TRI (especially, Dr. Frédérique Gaits-Iacovoni for helpful discussion) and 470 
Quantitative Transcriptomics facilities contributed to the work. 471 
This work was supported by Inserm, Paul Sabatier University, Fondation pour la Recherche 472 
Médicale (DEQ20170336720 to D.L.), Agence Nationale de la Recherche (ANR-12-BSV1-473 
0025Obelip and ANR-17-CE14-0015Hepadialogue to D.L.), Région Midi-Pyrénées (OBELIP 474 
and ILIP projects to D.L.), FORCE/F-CRIN for clinical research on obesity, EU/EFPIA 475 
Innovative Medicines Initiative Joint Undertaking (EMIF grant n° 115372 to P.A., A.V.P. and 476 
D.L.) and AstraZeneca France (TALIP project to D.L.). 477 
 478 
D.L. is a member of Institut Universitaire de France. 479 
 480 
AUTHOR CONTRIBUTIONS 481 
P.M. and M.H. share first authorship. P.M. and M.Ho. performed the majority of in vitro 482 
experiments and analyzed data with the contribution of A.Mai., C.G., F.B., B.M., E.R., 483 
P.D.D., V.Sr., V.B., D.B., M.M., C.L., L.L., F.L. and M.Ha. P.M., M.Ho., E.Mo., G.T., S.V., 484 
L.M., S.G., B.M.-R., T.S., H.G., C.H., A.V.P. and C.P. performed and analyzed in vivo data 485 
from mouse models. P.M., S.B., M.M., B.F., A.A., E.Me., C.L., R.R.L., W.S., V.St., P.A., 486 
M.R., N.V. and H.V. performed and analyzed in vivo data in human clinical studies. S.C.-B., 487 
S.V. and J.B.-M. analyzed lipidomics data. A.Maz. and M.Z. performed and analyzed FRAP 488 
Morigny, Houssier et al.  22 
experiments. B.P., C.M., N.V., S.H. and H.V. interpreted the data. P.M., M.Ho. and D.L. 489 
conceived the study, interpreted the data and wrote the manuscript. D.L. supervised the study. 490 
 491 
COMPETING INTERESTS STATEMENT 492 
T.S. is an employee of Physiogenex. M.H. and S.H. are employees of AstraZeneca. The other 493 
authors declare no competing financial and non-financial interests. 494 
  495 
Morigny, Houssier et al.  23 
REFERENCES 496 
1. Abel, E.D., et al. Adipose-selective targeting of the GLUT4 gene impairs insulin 497 
action in muscle and liver. Nature 409, 729-733 (2001). 498 
2. Morley, T.S., Xia, J.Y. & Scherer, P.E. Selective enhancement of insulin sensitivity in 499 
the mature adipocyte is sufficient for systemic metabolic improvements. Nat Commun 500 
6, 7906 (2015). 501 
3. Shearin, A.L., Monks, B.R., Seale, P. & Birnbaum, M.J. Lack of AKT in adipocytes 502 
causes severe lipodystrophy. Mol Metab 5, 472-479 (2016). 503 
4. Softic, S., et al. Lipodystrophy Due to Adipose Tissue Specific Insulin Receptor 504 
Knockout Results in Progressive NAFLD. Diabetes (2016). 505 
5. Rondinone, C.M., et al. Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the 506 
main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects 507 
with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 94, 4171-508 
4175 (1997). 509 
6. Carvalho, E., Jansson, P.A., Nagaev, I., Wenthzel, A.M. & Smith, U. Insulin 510 
resistance with low cellular IRS-1 expression is also associated with low GLUT4 511 
expression and impaired insulin-stimulated glucose transport. FASEB J 15, 1101-1103 512 
(2001). 513 
7. Frojdo, S., Vidal, H. & Pirola, L. Alterations of insulin signaling in type 2 diabetes: a 514 
review of the current evidence from humans. Biochim Biophys Acta 1792, 83-92 515 
(2009). 516 
8. Nyman, E., et al. A single mechanism can explain network-wide insulin resistance in 517 
adipocytes from obese patients with type 2 diabetes. J Biol Chem 289, 33215-33230 518 
(2014). 519 
Morigny, Houssier et al.  24 
9. Hammarstedt, A., Sopasakis, V.R., Gogg, S., Jansson, P.A. & Smith, U. Improved 520 
insulin sensitivity and adipose tissue dysregulation after short-term treatment with 521 
pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia 48, 96-104 522 
(2005). 523 
10. Yki-Jarvinen, H. Thiazolidinediones. N Engl J Med 351, 1106-1118 (2004). 524 
11. Samuel, V.T. & Shulman, G.I. Mechanisms for insulin resistance: common threads 525 
and missing links. Cell 148, 852-871 (2012). 526 
12. Karpe, F., Dickmann, J.R. & Frayn, K.N. Fatty acids, obesity, and insulin resistance: 527 
time for a reevaluation. Diabetes 60, 2441-2449 (2011). 528 
13. Girousse, A., et al. Partial inhibition of adipose tissue lipolysis improves glucose 529 
metabolism and insulin sensitivity without alteration of fat mass. PLoS Biol 11, 530 
e1001485 (2013). 531 
14. Bezaire, V., et al. Contribution of adipose triglyceride lipase and hormone-sensitive 532 
lipase to lipolysis in hMADS adipocytes. J Biol Chem 284, 18282-18291 (2009). 533 
15. Barquissau, V., et al. White-to-brite conversion in human adipocytes promotes 534 
metabolic reprogramming towards fatty acid anabolic and catabolic pathways. Mol 535 
Metab 5, 352-365 (2016). 536 
16. Eissing, L., et al. De novo lipogenesis in human fat and liver is linked to ChREBP-537 
beta and metabolic health. Nat Commun 4, 1528 (2013). 538 
17. Roberts, R., et al. Markers of de novo lipogenesis in adipose tissue: associations with 539 
small adipocytes and insulin sensitivity in humans. Diabetologia 52, 882-890 (2009). 540 
18. Grober, J., et al. Characterization of the promoter of human adipocyte hormone-541 
sensitive lipase. Biochem J 328, 453-461 (1997). 542 
Morigny, Houssier et al.  25 
19. Collins, J.M., Neville, M.J., Hoppa, M.B. & Frayn, K.N. De novo lipogenesis and 543 
stearoyl-CoA desaturase are coordinately regulated in the human adipocyte and 544 
protect against palmitate-induced cell injury. J Biol Chem 285, 6044-6052 (2010). 545 
20. Guillou, H., Zadravec, D., Martin, P.G. & Jacobsson, A. The key roles of elongases 546 
and desaturases in mammalian fatty acid metabolism: Insights from transgenic mice. 547 
Prog Lipid Res 49, 186-199 (2010). 548 
21. Hodson, L. & Fielding, B.A. Stearoyl-CoA desaturase: rogue or innocent bystander? 549 
Prog Lipid Res 52, 15-42 (2013). 550 
22. Ohno, Y., et al. ELOVL1 production of C24 acyl-CoAs is linked to C24 sphingolipid 551 
synthesis. Proc Natl Acad Sci U S A 107, 18439-18444 (2010). 552 
23. Nagase, T., et al. Synthesis and biological evaluation of a novel 3-sulfonyl-8-553 
azabicyclo[3.2.1]octane class of long chain fatty acid elongase 6 (ELOVL6) inhibitors. 554 
J Med Chem 52, 4111-4114 (2009). 555 
24. Xin, Z., et al. Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 556 
inhibitors. Bioorg Med Chem Lett 18, 4298-4302 (2008). 557 
25. Antonny, B., Vanni, S., Shindou, H. & Ferreira, T. From zero to six double bonds: 558 
phospholipid unsaturation and organelle function. Trends Cell Biol 25, 427-436 559 
(2015). 560 
26. Holzer, R.G., et al. Saturated fatty acids induce c-Src clustering within membrane 561 
subdomains, leading to JNK activation. Cell 147, 173-184 (2011). 562 
27. Bae, J.S., Oh, A.R., Lee, H.J., Ahn, Y.H. & Cha, J.Y. Hepatic Elovl6 gene expression 563 
is regulated by the synergistic action of ChREBP and SREBP-1c. Biochem Biophys 564 
Res Commun 478, 1060-1066 (2016). 565 
28. Herman, M.A., et al. A novel ChREBP isoform in adipose tissue regulates systemic 566 
glucose metabolism. Nature 484, 333-338 (2012). 567 
Morigny, Houssier et al.  26 
29. Filhoulaud, G., Guilmeau, S., Dentin, R., Girard, J. & Postic, C. Novel insights into 568 
ChREBP regulation and function. Trends Endocrinol Metab 24, 257-268 (2013). 569 
30. Stoeckman, A.K., Ma, L. & Towle, H.C. Mlx is the functional heteromeric partner of 570 
the carbohydrate response element-binding protein in glucose regulation of lipogenic 571 
enzyme genes. J Biol Chem 279, 15662-15669 (2004). 572 
31. Soderberg, O., et al. Direct observation of individual endogenous protein complexes in 573 
situ by proximity ligation. Nat Methods 3, 995-1000 (2006). 574 
32. Lou, D.Q., et al. Chicken ovalbumin upstream promoter-transcription factor II, a new 575 
partner of the glucose response element of the L-type pyruvate kinase gene, acts as an 576 
inhibitor of the glucose response. J Biol Chem 274, 28385-28394 (1999). 577 
33. Laurell, H., et al. Species-specific alternative splicing generates a catalytically inactive 578 
form of human hormone-sensitive lipase. Biochem J 328 ( Pt 1), 137-143 (1997). 579 
34. Ray, H., et al. The presence of a catalytically inactive form of hormone-sensitive 580 
lipase is associated with decreased lipolysis in abdominal subcutaneous adipose tissue 581 
of obese subjects. Diabetes 52, 1417-1422 (2003). 582 
35. Kusminski, C.M., Bickel, P.E. & Scherer, P.E. Targeting adipose tissue in the 583 
treatment of obesity-associated diabetes. Nat Rev Drug Discov (2016). 584 
36. Czech, M.P. Cellular basis of insulin insensitivity in large rat adipocytes. J Clin Invest 585 
57, 1523-1532 (1976). 586 
37. Hoffstedt, J., Forster, D. & Lofgren, P. Impaired subcutaneous adipocyte lipogenesis 587 
is associated with systemic insulin resistance and increased apolipoprotein B/AI ratio 588 
in men and women. J Intern Med 262, 131-139 (2007). 589 
38. Kursawe, R., et al. Decreased transcription of ChREBP-alpha/beta isoforms in 590 
abdominal subcutaneous adipose tissue of obese adolescents with prediabetes or early 591 
Morigny, Houssier et al.  27 
type 2 diabetes: associations with insulin resistance and hyperglycemia. Diabetes 62, 592 
837-844 (2013). 593 
39. Soronen, J., et al. Adipose tissue gene expression analysis reveals changes in 594 
inflammatory, mitochondrial respiratory and lipid metabolic pathways in obese 595 
insulin-resistant subjects. BMC Med Genomics 5, 9 (2012). 596 
40. Nilsson, E., et al. Altered DNA methylation and differential expression of genes 597 
influencing metabolism and inflammation in adipose tissue from subjects with type 2 598 
diabetes. Diabetes 63, 2962-2976 (2014). 599 
41. Matsuzaka, T., et al. Crucial role of a long-chain fatty acid elongase, Elovl6, in 600 
obesity-induced insulin resistance. Nat Med 13, 1193-1202 (2007). 601 
42. Ryan, M., et al. Diabetes and the Mediterranean diet: a beneficial effect of oleic acid 602 
on insulin sensitivity, adipocyte glucose transport and endothelium-dependent 603 
vasoreactivity. QJM 93, 85-91 (2000). 604 
43. Salas-Salvado, J., et al. Reduction in the incidence of type 2 diabetes with the 605 
Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized 606 
trial. Diabetes Care 34, 14-19 (2011). 607 
44. Ibarguren, M., et al. Partitioning of liquid-ordered/liquid-disordered membrane 608 
microdomains induced by the fluidifying effect of 2-hydroxylated fatty acid 609 
derivatives. Biochim Biophys Acta 1828, 2553-2563 (2013). 610 
45. Pietilainen, K.H., et al. Association of lipidome remodeling in the adipocyte 611 
membrane with acquired obesity in humans. PLoS Biol 9, e1000623 (2011). 612 
46. Moon, Y.A., Ochoa, C.R., Mitsche, M.A., Hammer, R.E. & Horton, J.D. Deletion of 613 
ELOVL6 blocks the synthesis of oleic acid but does not prevent the development of 614 
fatty liver or insulin resistance. J Lipid Res 55, 2597-2605 (2014). 615 
Morigny, Houssier et al.  28 
47. Lafontan, M. & Langin, D. Lipolysis and lipid mobilization in human adipose tissue. 616 
Prog Lipid Res 48, 275-297 (2009). 617 
48. Kraemer, F.B. & Shen, W.J. Hormone-sensitive lipase: control of intracellular tri-(di-618 
)acylglycerol and cholesteryl ester hydrolysis. J Lipid Res 43, 1585-1594 (2002). 619 
49. Postic, C. & Girard, J. Contribution of de novo fatty acid synthesis to hepatic steatosis 620 
and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118, 621 
829-838 (2008). 622 
50. Solinas, G., Boren, J. & Dulloo, A.G. De novo lipogenesis in metabolic homeostasis: 623 
More friend than foe? Mol Metab 4, 367-377 (2015). 624 
  625 
Morigny, Houssier et al.  29 
FIGURE LEGENDS 626 
Figure 1. Reduced HSL expression promotes glucose metabolism and insulin signaling in 627 
human adipocytes. Experiments were carried out in control (white bars, siCTR) and HSL-628 
deprived (grey bars, siHSL) hMADS adipocytes. (a-g) Adipocytes were analyzed in basal (-) 629 
and insulin-stimulated (+, 100nM) conditions. (a) Glucose transport using radiolabelled 2-630 
deoxyglucose (n=12 biologically independent samples per group) (Insulin stimulation: 631 
P<0.0001). (b) Glucose oxidation using radiolabelled glucose (n=10 biologically independent 632 
samples per group) (Insulin stimulation: P=0.0015). (c) de novo lipogenesis using 633 
radiolabelled glucose (n=10 biologically independent samples per group) (Insulin stimulation: 634 
P<0.0001). (d-g) Insulin signaling evaluated by activating phosphorylation of IRS1 (pY612) 635 
(n=7 biologically independent samples per group) (Insulin stimulation: P=0.0033) (d) AKT 636 
(pS473) (n=5 biologically independent samples per group) (Insulin stimulation: P=0.0005) 637 
(e), AKT (pT308) (n=8 biologically independent samples per group) (Insulin stimulation: 638 
P=0.0201) (f) and AS160 (pT642) (n=4 biologically independent samples per group) (Insulin 639 
stimulation: P=0.0726) (g). Size markers (in kDa) are shown on illustrative Western blot 640 
panels. (h, i) Fatty acid composition in triglycerides (TG) (h) and phospholipids (PL) (i) (n=8 641 
biologically independent samples per group). (j) mRNA levels of lipogenic enzymes (n=6 642 
biologically independent samples per group). Data are mean ±sem. Statistical analysis was 643 
performed using two-way ANOVA with Bonferroni’s post hoc tests (a-g), paired Student’s t 644 
test (h, i) and Wilcoxon’s test (j). Statistical tests were two-sided. *P<0.05, **P<0.01, 645 
***P<0.001 compared to control.  646 
 647 
Figure 2. HSL inhibition is associated with increased insulin sensitivity and adipose tissue 648 
ELOVL6 expression in vivo. (a-f) Experiments were carried out in wild type (WT, white bars) 649 
and HSL haploinsufficient (Lipe+/-, grey bars) mice. (a-c) Glucose infusion rate (GIR) (a) post 650 
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insulin glucose rate of disappearance (Glucose Rd) (b) and hepatic glucose production (HGP) 651 
(c) during euglycemic-hyperinsulinemic clamp in B6D2/F1 mice fed 60% high fat diet for 3 652 
months (WT n=7 animals, Lipe+/- n=6 animals). (d) Plasma glucose concentration during an 653 
insulin tolerance test in B6D2/F1 mice fed 45% high fat diet for 3 months (n=12 animals per 654 
group). (e) QUICKI and (f) mRNA level of Elovl6 in response to refeeding in gonadal 655 
adipose tissue (n=8 animals per group) in C57BL/6J mice fed 60% high fat diet for 3 months 656 
(n=8 animals per group). (g-j) Experiments were carried out in wild type (WT, white bars) 657 
and in mice with zinc finger nuclease-mediated deletion of Lipe exon B which promoter 658 
drives HSL expression in fat cells (LipeexonB-/-, grey bars). (g) mRNA levels of transcripts 659 
containing different exons encoding HSL in inguinal adipose tissue (n=12 animals per group). 660 
(h) Western blot analysis of adipose tissue HSL protein content (10 µg total protein) (WT n=7 661 
animals; LipeexonB-/- n =5 animals). GAPDH was used as Western blot loading control. Size 662 
markers (in kDa) are shown on illustrative Western blot panel. (i) Plasma glucose 663 
concentration and area under the curve (AUC) during a glucose tolerance test (WT n=7 664 
animals, LipeexonB-/- n=5 animals) in mice fed 60% high fat diet for 3 weeks and (j) mRNA 665 
level of adipose tissue Elovl6 (WT n=5 animals,  LipeexonB-/- n=6 animals). Data are mean 666 
±sem. Statistical analysis was performed using Mann and Whitney’s test (a-c, h-j), unpaired 667 
Student’s t test (e-g) or two-way ANOVA with Bonferroni’s post-hoc tests (d). Statistical 668 
tests were two-sided. *P<0.05 compared to control. 669 
 670 
Figure 3. ELOVL6 has a positive effect on insulin signaling in adipocytes. (a, b) Experiments 671 
were carried out in control (white bars, siCTR), single HSL (grey bars, siHSL), single 672 
ELOVL6 (light orange bars, siELOVL6) or dual HSL/ELOVL6-deprived (dark orange bars, 673 
siHSL/siELOVL6) hMADS adipocytes in basal (-) and insulin-stimulated (+, 100nM) 674 
conditions. Insulin signaling evaluated by activating phosphorylation of IRS1 (pY612) (n=7 675 
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biologically independent samples per group) (Insulin stimulation: P=0.0238) (a) and AKT 676 
(pS473) (n=7 biologically independent samples per group) (Insulin stimulation: P<0.0001) 677 
(b). (c) Insulin signaling evaluated by activating phosphorylation of AKT (pS473) in wild 678 
type (WT, white bars, n=4 animals) and Elovl6 null (Elovl6-/-, light orange bars, n=3 animals) 679 
mice injected with a bolus of insulin (Insulin stimulation: P<0.0001). Size markers (in kDa) 680 
are shown on illustrative Western blot panels. (d, e) Plasma glucose concentration during an 681 
insulin tolerance test (n=9 animals per group) (d) and gonadal adipose tissue Elovl6 mRNA 682 
levels in response to refeeding (e) in DBA/2J (white bars, n=6 animals) and C57Bl/6J (light 683 
green bars, n=5 animals) mice. (f, g) Glucose disposal rate (GDR) (f) and mRNA level of 684 
ELOVL6 in visceral adipose tissue (g) from lean healthy (LE, white bars, n=13 individuals) 685 
and obese women with metabolic syndrome (MS, light red bars, n=15 individuals). (h, i) M-686 
value (h) and normalized ELOVL6 mRNA level (i) in subcutaneous adipose tissue of obese 687 
women before and two years after bariatric surgery (n=14 individuals). Data are mean ±sem. 688 
Statistical analysis was performed using paired (a, b, d) and unpaired (c) two way ANOVA 689 
with Bonferroni’s post hoc tests, unpaired Student’s t test (f), Mann and Whitney’s test (e, g), 690 
and Wilcoxon’s test (h, i). Statistical tests were two-sided. *P<0.05, **P<0.01, ***P<0.001 691 
compared to control condition or other mouse strain. In cell experiments, $$P<0.01, 692 
$$$P<0.001 compared to HSL-deprived adipocytes. 693 
 694 
Figure 4. Oleic acid content in PL and plasma membrane fluidity mediates ELOVL6 positive 695 
effect on insulin signaling. (a-h) Experiments were carried out in control (white bars, siCTR), 696 
single HSL (grey bars, siHSL), single ELOVL6 (light orange bars, siELOVL6) or dual 697 
HSL/ELOVL6-deprived (dark orange bars, siHSL/siELOVL6) hMADS adipocytes. (a, b) 698 
Fatty acid composition in TG (a) and PL (b) (n=6 biologically independent samples per 699 
group). (c-f) hMADS adipocytes were treated with vehicle (DMSO), 1µM of ELOVL6 700 
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inhibitor (ELOVL6i) or 75nM of SCD inhibitor (SCDi) for 48h. Fatty acid ratios (n=6 for 701 
ELOVL6i and n=5 for SCDi biologically independent samples per group) (c,e) and insulin 702 
signaling evaluated by activating phosphorylation of AKT (pS473) in basal (-) and insulin-703 
stimulated conditions (+,100nM) (n=4 biologically independent samples per group for 704 
ELOVL6i and SCDi) (Insulin stimulation: P<0.0001) (d,f). DMSO-treated adipocyte values 705 
are common to panels d and f and, Supplementary Fig. 1e. (g, h) hMADS were treated with 706 
vehicle (V), 100µM (O100) or 500µM (O500) of oleic acid for 48h. Oleic acid levels in PL 707 
(n=5 biologically independent samples per group) (g) and insulin signaling evaluated by 708 
activating phosphorylation of AKT (pS473) (n=5 biologically independent samples per group) 709 
in basal (-) or insulin-stimulated (+, 100nM) conditions (Insulin stimulation: P=0.0003) (h). 710 
For panels d, f and h, cropped images of vehicle and treatment lanes originate from the same 711 
blot. Size markers (in kDa) are shown on illustrative Western blot panels. (i-l) Experiments 712 
were carried out in control hMADS adipocytes expressing green fluorescent protein (GFP) 713 
(white bars, Adeno-CTR) or overexpressing human ELOVL6 and GFP (avocado bars, Adeno-714 
ELOVL6). (i, j) Fatty acid ratio (n=8 biologically independent samples per group) (i) and 715 
activating phosphorylation of IRS1 (pY612) in basal (-) and insulin-stimulated conditions (+, 716 
100nM) (n=8 biologically independent samples per group) (Insulin stimulation: P<0.0001) (j). 717 
(k, l) FRAP experiments using fluorescent cholera toxin B (Alexa555-CTxB) (n=5 718 
independent experiments). (k) Representative confocal microscope image showing GFP and 719 
Alexa455-CTxB at room temperature of a successfully transduced hMADS adipocyte. Scale 720 
bar, 50µm. (l) Calculated mobile fraction (white bar, n=17 analyzed cells; avocado bar, n=16 721 
analyzed cells). Data are mean ±sem. Statistical analysis was performed using Wilcoxon’s test 722 
(a,b), paired (c-f, h, j) and unpaired (d) two way ANOVA with Bonferroni’s post hoc tests, 723 
Friedman’s with Dunn’s post hoc tests (g), paired Student’s t test (i) and Mann and Whitney’s 724 
test (l). Statistical tests were two-sided. *P<0.05, **P<0.01, ***P<0.001 compared to control. 725 
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$$P<0.01, $$$P<0.001 compared to HSL-deprived adipocytes. #P<0.05, ##P<0.01 compared to 726 
HSL- and ELOVL6-deprived adipocytes.  727 
 728 
Figure 5. The glucose-sensitive transcription factor, ChREBP, mediates the beneficial effect 729 
of diminished HSL expression on glucose metabolism and insulin signaling in adipocytes. (a-730 
e) Experiments were carried out in control (white bars, siCTR), single HSL (grey bars, 731 
siHSL), single ChREBP (light brown bars, siChREBP) or dual HSL/ChREBP-deprived (dark 732 
brown bars, siHSL/siChREBP) hMADS adipocytes in basal (-) and insulin-stimulated (+, 733 
100nM) conditions. (a) Glucose transport using radiolabelled 2-deoxyglucose (n=12 734 
biologically independent samples per group) (Insulin stimulation: P<0.0001). (b, c) de novo 735 
lipogenesis using radiolabelled glucose (n=9 biologically independent samples per group) 736 
(Insulin stimulation: P=0.0002) (b) or radiolabelled acetate (n=6 biologically independent 737 
samples per group) (Insulin stimulation: P=0.0014) (c). (d, e) Insulin signaling evaluated by 738 
activating phosphorylation of IRS1 (pY612) (n=8 biologically independent samples per 739 
group) (Insulin stimulation: P=0.0245) (d) and AKT (pS473) (n=8 biologically independent 740 
samples per group) (Insulin stimulation: P<0.0001) (e). Size markers (in kDa) are shown on 741 
illustrative Western blot panels. (f-h) Experiments were carried out in control (white bars, 742 
siCTR) and ChREBP-deprived (light brown bars, siChREBP) hMADS adipocytes. (f, g) Fatty 743 
acid composition in TG (f) and PL (g) (n=8 biologically independent samples per group). (h) 744 
mRNA levels of lipogenic enzymes (n=6 biologically independent samples per group). (i) 745 
mRNA levels of lipogenic enzymes in inguinal adipose tissue of wild type (WT, white bars, 746 
n=7 animals) and ChREBP null mice (Mlxipl-/-, light brown bars, n=6 animals). (j,k) 747 
Experiments were carried out in control (white bars, siCTR) and HSL-deprived (grey bars, 748 
siHSL) hMADS adipocytes. (j) Induction of mRNA levels of ChREBPα and ChREBPβ (n=8 749 
biologically independent samples per group) and (k) ChREBP recruitment on ELOVL6 750 
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ChoRE (n=3 independent experiments). (l, m) Correlations between mRNA levels of 751 
ELOVL6 and ChREBPβ in hMADS adipocytes (n=64 biologically independent samples) (l) 752 
and in human subcutaneous adipose tissue (n=31 individuals) (m). (n, o) mRNA levels of 753 
ChREBPβ (n=7 biologically independent samples per group) (n) and ELOVL6 (n=7 754 
biologically independent samples per group) (o) in human subcutaneous adipose tissue in 755 
basal condition or during hyperglycemic-hyperinsulinemic clamp. Data are mean ±sem. 756 
Statistical analysis was performed using paired two way ANOVA with Bonferroni post hoc 757 
tests (a-e), paired Student’s t test (f, g, j), Wilcoxon’s test (h, n, o), Mann and Whitney’s test 758 
(i) and linear regression (l, m). Statistical tests were two-sided. *P<0.05, **P<0.01, 759 
***P<0.001 compared to control. $P<0.05, $$P<0.01, $$$P<0.001 compared to HSL-deprived 760 
adipocytes. #P<0.05, ##P<0.01 compared to ChREBP-deprived adipocytes. 761 
 762 
Figure 6. HSL inhibits ChREBP activity through protein-protein interaction. (a) 763 
Representative image of immunocomplexes between immobilized FLAG-ChREBPα and 764 
recombinant HSL (Rec.HSL) (n=3 independent experiments). (b) Representative surface 765 
plasmon resonance assay sensorgram showing the binding of HSL to ChREBP. Purified 766 
ChREBP (220RU) was first injected on a sensorchip with immobilized anti-ChREBP 767 
antibody. Following ChREBP binding, PR65α (no signal) and HSL (35RU) were 768 
consecutively injected (n=3 independent experiments). (c) Endogenous interaction between 769 
HSL and ChREBP in human adipocytes (n=3 biologically independent samples per group). 770 
Anti-ChREBP antibody was used for immunoprecipitation (IP). Normal Rabbit IgG antibody 771 
was used as negative control. (d) Endogenous interaction between HSL and ChREBP in white 772 
adipose tissue of Lipe+/- (+/-) and wild type (+/+) mice (n=4 animals per group). Anti-773 
ChREBP antibody was used for immunoprecipitation. Rabbit IgG antibody was used as 774 
negative control. β-actin was used as Western blot loading control.  (e) In situ proximity 775 
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ligation assays (red signals) performed with anti-HSL and anti-ChREBP antibodies (PLA 776 
HSL/ChREBP) and corresponding image under visible light (Phase) in control (siCTR) and 777 
HSL-deprived (siHSL) hMADS adipocytes. Nuclei were labelled in blue using DAPI. 778 
Representative image (6 independent experiments). Scale bars, 50µm. (f) Immunodetection of 779 
ChREBP (red) in control (siCTR) and HSL-deprived (siHSL) hMADS adipocytes. 780 
Representative image (4 independent experiments). Nuclei were labelled in blue using DAPI. 781 
Scale bars, 50µm. (g) ChREBPα protein levels in nuclear extracts from control (siCTR) and 782 
HSL-deprived (siHSL) hMADS adipocytes (n=8 biologically independent samples per 783 
group). (h) ChREBPα protein levels in nuclear extracts from white adipose tissue of wild type 784 
(WT, n=8 animals) and Lipe+/- (n=9 animals) mice. (i) Luciferase assays following 785 
transfection in HEK-293 cells of carbohydrate-responsive elements (ChoRE) fused to the 786 
luciferase gene along with expression vectors for ChREBP and HSL. ChoRE activity was 787 
measured in HEK-293 cells transfected with empty plasmid (pcDNA), ChREBP and different 788 
concentrations of HSL expression plasmids under low (5mM, G5) (n=6 biologically 789 
independent samples per group) and high (25mM, G25) glucose concentrations (n=4 790 
biologically independent samples per group). (j) HSL and ChREBPα immunocomplexes in 791 
HEK-293 cells transfected with empty plasmid (pcDNA3), FLAG-ChREBP, full lengh HSL 792 
(HSL) or short form HSL (HSL-S) expression plasmids. Anti-FLAG antibody was used for 793 
immunoprecipitation. β-actin was used as Western blot loading control (n=3 independent 794 
experiments) (k,l) Effect of overexpression of the short inactive form of HSL (HSL-S) in 795 
hMADS adipocytes. Experiments were carried out in control (siCTR, white bars) and HSL-796 
deprived (siHSL, grey bars) hMADS adipocytes overexpressing green fluorescent protein 797 
(GFP, Ad-CTR) or the short inactive form of HSL (Ad-HSL-S). (k) mRNA levels of ELOVL6 798 
(n=10 biologically independent samples per group). (l) Activating phosphorylation of IRS1 799 
(pY612) in basal (-) and insulin-stimulated (+, 100nM) conditions (n=6 biologically 800 
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independent samples per group, Insulin stimulation: P<0.0001). Size markers (in kDa) are 801 
shown on illustrative Western blot panels. Data are mean ± sem. Statistical analysis was 802 
performed using paired Student’s t test (g), Mann and Whitney’s test (h) or paired two-way 803 
ANOVA with Bonferroni’s post-hoc tests (i, k, l). Statistical tests were two-sided. *P<0.05, 804 
**P<0.01 ***P<0.001 compared to ChREBP condition (i) or control adipocyte (l). $P<0.05, 805 
$$$P<0.001 compared to pcDNA condition (i) or siHSL/Ad-CTR adipocytes (k, l). 806 
  807 
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METHODS 808 
General experimental approaches. No samples, mice, human research participants and data 809 
points were excluded from the reported analysis. Randomization was not performed. Analyses 810 
were not blinded except when noted below. Detailed information and description of common 811 
techniques are described in Supplementary Methods as indicated below. 812 
Culture of human adipocytes and in vitro measurements.  813 
Culture of adipocytes. hMADS cells were expanded in DMEM 5.5 mM glucose (Lonza) 814 
supplemented with 10% fetal bovine serum (Lonza), 2 mM L-glutamine (Invitrogen), 10 mM 815 
HEPES buffer (Lonza), 50 units/ml of penicillin (Invitrogen), 50 mg/ml of streptomycin 816 
(Invitrogen), supplemented with 2.5 ng/ml of  fibroblast growth factor 2  (Sigma). At 817 
confluence, fibroblast growth factor 2 was removed from proliferation medium. On the next 818 
day (day 0), the cells were incubated in differentiation medium (DMEM/Ham’s F-12 medium 819 
containing 7.8 mM glucose, HEPES, L-glutamine, penicillin/streptomycin, 10 µg/ml of 820 
transferrin (Sigma), 10nM of insulin (Sigma), 0,2 nM triiodothyronine (Sigma), 100 µM 3-821 
isobutyl-1-methylxanthine (Sigma), 1 µM dexamethasone (Sigma), and 100 nM rosiglitazone 822 
(Sigma)). At days 3 and 10, respectively, dexamethasone and 3-isobutyl-1-methylxanthine, 823 
and then rosiglitazone were removed from culture medium. The experiments were carried out 824 
between days 12 and 15.  825 
For primary culture and differentiation of human preadipocytes, subcutaneous adipose tissue 826 
samples were obtained from 5 women (age 39 ± 9 years; BMI 28 ± 4 kg/m2) undergoing 827 
elective plastic surgery in the abdominal or dorsal region at Rangueil Hospital, Toulouse, 828 
France. Adipose tissue was cleaned from blood vessels and fibrous material, minced into 829 
pieces and digested in 1 volume of collagenase I (300 units/ml, Sigma) for 90 min in 37 °C 830 
shaking water bath. Digested tissue was filtered through 250 μm strainer, diluted with 831 
PBS/gentamycin and centrifuged at 1300 rpm for 5 min. Pellet was incubated in erythrocyte 832 
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lysis buffer for 10 min at room temperature. Cells were filtered, centrifuged, resuspended in 833 
PM4 medium with 132 nmol/L insulin for differentiation and collected at day 13 51,52. The 834 
study was approved by the Ethics Committee of Toulouse University Hospitals (Comité de 835 
Protection des Personnes Sud Ouest et Outre Mer 2, DC-2014-2039). The volunteers signed 836 
informed consent for anonymous use of samples. 837 
HEK293 and HepG2 cell cultures. See Supplementary Methods. 838 
RNA interference. RNA interference was achieved by small interfering RNA (siRNA). 839 
Briefly, on day 7 and day 4 of differentiation respectively, hMADS and primary 840 
preadipocytes were detached from culture dishes with trypsin/EDTA (Invitrogen) and 841 
counted. Control small interfering RNA against Green Fluorescent Protein (siCTR) and gene-842 
specific siRNA for HSL, ChREBP, ELOVL6 and ATGL (Eurogentec) were delivered into 843 
adipocytes using a microporator (Invitrogen) with the following parameters: 1,100 V, 20 ms, 844 
1 pulse. The targeted sequences are provided in Supplementary Methods.  845 
Adenoviral infection. Adenoviruses encoding under the control of a cytomegalovirus 846 
promoter, ELOVL6 (ADV-207862), the short form of HSL, both in tandem with GFP, or GFP 847 
alone (catalog No. 1060) were obtained from Vector Biolabs. Adenoviral particles 848 
(multiplicity of infection, 200) were added in the culture medium for 24 hours at day 11-12 of 849 
hMADS cell differentiation. Medium was changed and experiments were carried out 48 hours 850 
later. 851 
Plasmid transfection. See Supplementary Methods. 852 
Oleic acid supplementation in human adipocytes. See Supplementary Methods. 853 
Treatments with enzyme inhibitors. For FAS, SCD and ELOVL6 inhibition, hMADS 854 
adipocytes were respectively treated with 1µM of compound AZ12756122 (ex 117 from 855 
WO2008075070A1, synthesized at AstraZeneca), 75nM of A939572 24 (Tocris Biosciences) 856 
and 1w 23 (provided by AstraZeneca) in culture medium for 48 hours. To study the effect of 857 
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bioactive FA on the induction of ChREBP, cells were treated for 8h with 10µM of triacsin C 858 
(Sigma), an inhibitor of acyl-CoA synthase, in the culture medium. 859 
Gene expression analysis. See Supplementary Methods. 860 
Characterization of human ChREBPβ-specific exon. See Supplementary Methods. 861 
Western blot analysis. See Supplementary Methods. 862 
Metabolic measurements. Triacylglycerol hydrolase activity was measured on cell extracts 14. 863 
For other metabolic measurements, insulin was removed from culture medium the day before 864 
the assay. To determine glucose uptake, cells were incubated 50 min at 37°C with or without 865 
100 nM insulin. Then, 125 µM of cold 2-deoxy-Dglucose and 0.4 µCi 2-deoxy-D-[3H] 866 
glucose (Perkin Elmer) per well were added for 10 min incubation. Culture plates were put on 867 
ice and rinsed with 10 mM glucose in ice-cold PBS and then with ice-cold PBS. Cells were 868 
scraped in 0.05N NaOH, and radioactive 2-deoxy-D-glucose uptake was measured by liquid 869 
scintillation counting of cell lysate. To determine glucose oxidation, cells were incubated for 870 
3 h in Krebs Ringer buffer supplemented with 2% BSA, 10 mM HEPES, 2 mM glucose, and 871 
1 µCi D-[14C(U)]glucose (PerkinElmer) with or without 100 nM insulin. A 2x2 cm Whatman 872 
3M paper was placed on top of each well and soaked with 120 µL NaOH 1N. After 873 
incubation, filter-trapped 14CO2 was measured by liquid scintillation counting. Medium was 874 
acidified with 1M sulfuric acid and medium 14CO2 was trapped by benzethonium hydroxide, 875 
during 2 h incubation. Benzethonium-trapped 14CO2 was measured by liquid scintillation 876 
counting. Specific activity was counted and used to determine the quantity of oxidized 877 
glucose equivalent. To assess glucose incorporation into FA, cells were then washed twice in 878 
PBS and then scraped in STED. Neutral lipids were extracted in methanol/chloroform (1:2). 879 
Organic phase was dried under nitrogen and hydrolyzed in 1mL 0.25N NaOH in 880 
methanol/chloroform (1:1) for 1 h at 37°C. The solution was neutralized with 500 µL 0.5N 881 
HCl in methanol. FAs and glycerol were separated by adding 1.7 mL chloroform, 860 µL 882 
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water, and 1 mL methanol/chloroform (1:2). Incorporation of 14C into FAs was measured by 883 
liquid scintillation counting of the lower phase. Specific activity was counted and used to 884 
determine the quantity of incorporated glucose equivalent. De novo lipogenesis was also 885 
measured using acetic acid-sodium salt-[1-14C] (PerkinElmer). Cells were incubated for 3h in 886 
Krebs buffer supplemented with 10mM HEPES, 2mM glucose, 2%BSA and 2µCi/mL of 887 
radiolabelled acetate stimulated with or without 100nM insulin. Cells were then washed twice 888 
and harvest in PBS/SDS 0.1%. Neutral lipids were extracted in methanol/chloroform (1:2) 889 
method. Incorporation of 14C into neutral lipids was measured by liquid scintillation counting 890 
of lower phase. Results from metabolic measurements were normalized to total protein 891 
content of cell extracts. 892 
ELOVL6 activity. Fatty acid elongation activity was measured in crude microsomal extracts 893 
from hMADS adipocytes 41. Briefly, cells were washed with PBS, scraped in 3 ml of ice-cold 894 
250m M sucrose, Hepes 20 mM, EDTA 1 mM, pH 7.5 and dounce-homogenized. 895 
Homogenate was centrifuged 1000 g at 4°C for 7 min. Supernatant was collected and 896 
centrifuged at 2000 g at 4°C for 30 min. Supernatant was collected and centrifuged at 17000 g 897 
at 4°C for 1 hour. The resultant pellet was suspended in 50 µl of 100 mM Tris-HCl, pH 7.4 898 
and used for fatty acid elongation activity after determination of protein concentration. 899 
ELOVL6 activity was essayed by the measurement of [2-14C]malonyl-CoA (Perkin Elmer) 900 
incorporation into exogenous palmitoyl-CoA 53. ELOVL6 inhibitor (1µM of compound 1w 23) 901 
was preincubated 30 min at 37°C with microsomal protein before addition of reaction 902 
mixture. Incubation was stopped by adding 0.2 ml of 5M KOH, 10% methanol and saponified 903 
at 65°C for 1h. Then the samples were cooled and acidified with 0.2 ml of ice-cold 5N HCl 904 
and 0.2 ml of ethanol. Free fatty acids were extracted from the mixture three times with 1 ml 905 
of hexane, 2% acetic acid. The pooled hexane fractions were dried under nitrogen and after 906 
addition of 3 ml of scintillation cocktail, the radioactivity incorporated was counted. Blanks 907 
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were carried out in parallel reactions incubated without microsomal fractions. ELOVL6 908 
activity obtained by subtracting [14C]malonyl-CoA molecules incorporated into fatty acids in 909 
the absence of inhibitor to the values in the presence of the ELOVL6 inhibitor. 910 
Chromatin immunoprecipitation assays. Human adipocyte cells (107 cells per condition) were 911 
fixed with 1% formaldehyde for 15 min and quenched with 0.125 M glycine. Chromatin was 912 
isolated by the addition of lysis buffer, followed by disruption with a Dounce homogenizer. 913 
Lysates were sonicated and the DNA sheared to an average length of 300-500 bp. Genomic 914 
DNA (Input) was prepared by treating aliquots of chromatin with RNase, proteinase K and 915 
heat for de-crosslinking, followed by ethanol precipitation (Active Motif Inc.). Pellets were 916 
resuspended and the resulting DNA was quantified on a NanoDrop spectrophotometer. 917 
Extrapolation to the original chromatin volume allowed quantitation of the total chromatin 918 
yield. Aliquots of chromatin (30 µg) were precleared with protein A agarose beads 919 
(Invitrogen). Genomic DNA regions of interest were isolated using an antibody against 920 
ChREBP (Novus, cat# NB400-135). Positive and negative controls were designed by Active 921 
Motif Inc. Complexes were washed, eluted from the beads with SDS buffer, and subjected to 922 
RNase and proteinase K treatment. Crosslinks were reversed by incubation overnight at 65 C, 923 
and ChIP DNA was purified by phenol-chloroform extraction and ethanol precipitation. 924 
Quantitative PCR reactions were carried out in triplicate using SYBR Green Supermix (Bio-925 
Rad, Cat # 170-8882) on a CFX Connect™ Real Time PCR system. Positive and negative 926 
control sites were tested for each factor as well as the sites of interest. The resulting signals 927 
were normalized for primer efficiency by carrying out qPCR for each primer pair using input 928 
DNA (pooled unprecipitated genomic DNA from each sample).  929 
Cellular subfractionation. Nuclear and cytosolic fractions from hMADS adipocytes were 930 
prepared using Nuclear Extract Kit (40010) from Active Motif. Cells were rinsed with PBS 931 
and immediately scrapped into 1X Hypotonic Buffer. For adipose tissue, tissues were ground 932 
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in liquid nitrogen and lysed using the NE-PER nuclear and cytoplasmic extraction reagent kit 933 
(Thermoscientific, 78835). Subsequent steps followed the manufacturer’s protocol. Anti-934 
histone H3 (4499, Cell Signaling Technology), anti-lamin A/C (4777, Cell Signaling 935 
Technology) and α tubulin (T5168, Sigma) antibodies were used to analyze the efficiency of 936 
cellular fractionation. 937 
Fatty acid composition of TG and PL. Cells were scraped in PBS and then mixed with 938 
methanol supplemented with butylated hydroxytoluene (BHT) 0.001%. Lipid extraction was 939 
performed with a chloroform/methanol mixture (1:1) and KCl (0.5 M) after centrifugation 940 
(2500rpm, 10min). PL and TG were isolated by thin-layer chromatography on silica glass 941 
plates (Merck) using petroleum ether/diethyl ether/acetic acid (80:20:1) as the mobile phase. 942 
FA methyl esters were generated by transmethylation of the glycerolipids in methanol with 5 943 
% acetyl chloride at 60°C for 1 hour, extracted 2 times by isooctane. Analysis was carried out 944 
with a gas chromatograph (Shimadzu GC 2100) equipped with a CP-Wax 58 capillary 945 
column, 50 m in length, 0.25-mm external diameter and 0.2-μm thickness of the stationary 946 
phase (Varian Inc.), with helium 1 mL/min as carrier gas. Programmed temperature 947 
vaporization (PTV system) injector and flame ionization detector were used. Results are 948 
expressed in percentage of total FA contained in the sample. 949 
Fatty acid composition in phospholipid classes. See Supplementary Methods.  950 
Measurement of glycerol and NEFA in culture medium. See Supplementary Methods. 951 
Fluorescence recovery after photobleaching (FRAP). Cells were labeled for 15 min with 952 
1µg/ml Alexa 555-labeled Cholera ToxinSubunit B (CTxB Molecular Probes) at 4°C, then 953 
washed three times in chilled medium supplemented with 25 mM HEPES buffer, pH 7.4. 954 
LSM780 confocal microscope, equipped with a high sensitive 32 channel GaAsP detectors, 955 
operated with Zen Black software, coupled to a DPSS-laser (561 nm, maximum power 20 956 
mW) was used for excitation with a detection bandwidth of 571-624 nm (Carl Zeiss). All 957 
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experiments were done at room temperature (22°C). Cells were observed using a Plan-958 
Apochromat 63X NA 1.4 oil immersion objective, and the pixel dwell was set to the optimal 959 
value of 1.92 µs. The fluorescence intensity of three regions of interest of 6.4 μm×3.2 μm was 960 
measured: the photobleached area, a region within the cell that was not photobleached to 961 
check for overall photobleaching and cell position fluctuation and the background. After 10 962 
prebleach scans (one scan every 200 ms) at 1% maximal laser power to determine initial 963 
fluorescence intensity, one photobleaching scan was performed at 100% laser power. Post 964 
bleach fluorescence recovery was then sampled at 1% laser power for 150 s. FRAP data 965 
analysis was done using the method described by Bonneau et al. 54. 966 
Immunoprecipitation. HEK293T cells were harvested in a lysis buffer containing 3% NaCl 967 
5M, 5% TrisHCl 1M (pH 7.5), 1% EDTA 500mM, 1.338% PPiNa and 0.02% NaF, 968 
supplemented with 1% Triton X-100 (Sigma), 2% 50X protease inhibitor cocktail (Roche) 969 
and 1% 1mM orthovanadate (Sigma). 1 mg of proteins was immunoprecipitated overnight at 970 
4°C, with 40µL of anti-FLAG M2 magnetic beads (Sigma). Beads were gently centrifuged for 971 
1 min and washed with the lysis buffer before elution in Laemmli buffer.  972 
For immunoprecipitation between purified proteins, FLAG-tagged ChREBP was expressed in 973 
HEK293T cells. Cells were harvested in lysis buffer described above. 300 μg of proteins was 974 
immunoprecipitated overnight at 4°C with 40µL of anti-FLAG M2 magnetic beads. Beads 975 
bound with ChREBP were washed with the lysis buffer and incubated with 1 μg of human 976 
recombinant HSL (Cayman) in 350 μl of lysis buffer for 3h at 4 °C with gentle rocking. The 977 
beads were washed 3 times with lysis buffer. 978 
For endogenous co-immunoprecipitation in hMADS adipocytes, cells were lysed for 15min in 979 
1X hypotonic buffer (Active Motif) with 4% 25X protease inhibitor cocktail (Roche) and 980 
1mM orthovanadate (Sigma). Cell debris and fat was discarded after 12700rpm centrifugation 981 
at 4°C for 15min. Preclearing was performed at 4°C for 30min using 50µL protein G and 4µg 982 
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control rabbit (2729, Cell Signaling Technology) or mouse (sc-2025, Santa Cruz)  IgG. Beads 983 
were discarded and supernatants were incubated with 4µg anti-ChREBP (NB400-135, Novus) 984 
ou 2µg anti-HSL (sc-74489, Santa Cruz Biotechnology) for 90 min at 4°C. As negative 985 
control of immunoprecipitation, 4µg control rabbit (2729, Cell Signaling Technology) or 2µg 986 
mouse (sc-2025, Santa Cruz) IgG were used. Protein A/protein G (50:50) magnetic beads 987 
were added for 1h at 4°C. Beads were washed in cold PBS with 4% 25X EDTA and 1mM 988 
orthovanadate.  989 
For ChREBP immunoprecipitation in mouse white adipose tissue, fat was cut in small pieces 990 
and lysed during 2h in 20 mM Tris/HCl, 150 mM NaCl, 0.5% NP-40 and 991 
protease/phosphatase inhibitors; pH 8. Following centrifugation at 15000g for 20 min at 4°C, 992 
fat layer was removed before collecting the supernatant. For each immunoprecipitation, 0.8 to 993 
1 mg of protein was precleared with 50 µl of Protein A Dynabeads (ThermoFisher) for 1h at 994 
4°C, then incubated overnight at 4°C with 40µl Protein A dynabeads coupled with 5µg Rabbit 995 
IgG or ChREBP antibody (Novus). Beads were washed 4 time with lysis buffer prior elution 996 
in 2X Laemmli buffer. 997 
In situ proximity ligation assay and immunofluorescence. In situ proximity ligation assay was 998 
performed using Duolink In Situ reagents (Sigma). Cells and pieces of subcutaneous adipose 999 
tissue were fixed with 4% paraformaldehyde (Sigma) and permeabilized 15 min at room 1000 
temperature with 0.2% Triton X-100 (Sigma). Incubation of antibodies, ligation of 1001 
oligodeoxynucleotides and amplification were performed following manufacturer’s 1002 
instructions. The following primary antibodies were incubated overnight at 4°C: anti-HSL 1003 
(murine antibody, sc-74489, Santa Cruz Biotechnology), anti-ATGL (mouse antibody, NBP2-1004 
59390, Novus), anti-AKT (mouse antibody, 2920, Cell Signaling Technology) and anti-1005 
ChREBP (rabbit antibody, NB400-135, Novus). The same antibodies were used in 1006 
immunofluorescence assays. Anti-mouse (Alexa-fluor 488-conjugated, A21202, and Alexa-1007 
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fluor 546-conjugated, A10036, Invitrogen) and anti-rabbit (Alexa-fluor 546-conjugated, 1008 
Invitrogen) secondary antibodies were incubated at 1/300 for 45min. Neutral lipids were 1009 
stained using Bodipy (4-3922, Life Technologies) for 30min. Nucleus labeling was performed 1010 
using Hoescht (33342, 5mg/mL, Invitrogen) for 5 min. Confocal microscopy was performed 1011 
using Zeiss LSM780. Image processing was similar for all conditions. The same settings were 1012 
applied to entire images. 1013 
Surface Plasmon Resonance assays. All binding studies based on surface plasmon resonance 1014 
technology were performed on BIAcore T200 optical biosensor instrument (GE Healthcare).  1015 
Immobilization of anti-ChREBP antibody (NB400-135, Novus) was performed by the Fc 1016 
region to the chip surface using native Protein A sensorchip in PBS-P+ buffer (20mM 1017 
Phosphate Buffer pH 7.4, 2.7mM Kcl, 137mM NaCl, and 0.05% surfactant P20) (GE 1018 
Healthcare). Immobilization step were performed at a flow rate of 5 µl/min with a final 1019 
concentration of 2µg/ml. Total amount of immobilized antibody was 11000-12000RU. Then 1020 
all injection steps were performed at a flow rate of 20µl/min.Channel Fc1 was used as a 1021 
reference surface for non-specific binding measurements. 1022 
Luciferase activity. See Supplementary Methods. 1023 
 1024 
Animal studies. No randomization and blinding was performed. Animals from several litters 1025 
were used in each protocol to avoid litter-to-litter variation. 1026 
Mouse models. Targeted disruption of the Lipe gene and generation of Lipe+/- mice have been 1027 
described elsewhere 13. Before euthanasia, mice were fasted for 24h or refed for 18h 1028 
supplemented with 20% glucose in drinking water. To create transgenic mice with specific 1029 
deletion of Lipe exon B, mRNA coding for zinc finger nucleases targeting specifically HSL 1030 
(CompoZr™ Custom Zinc Finger Nucleases, CSTZFN-1KT, Sigma) was injected into 1031 
pronuclei of one-cell embryos from female B6D2/F1 mice. Homozygous mice (LipeexonB-/-1032 
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registered as B6D2-Lipeem1Land mice) were obtained. Full description of the model will be 1033 
published elsewhere. The specific inhibitor of HSL (BAY 59-9435) was synthesized by 1034 
NoValix (Illkirch, France) 55. Transgenic mice were fed high fat diet (60% or 45% kcal fat, 1035 
respectively, D12492 and D12451 from Research Diets) for indicated times. In 1036 
pharmacological studies, C57BL/6J male mice (12-15 weeks-old, Janvier Laboratories) were 1037 
treated orally with DMSO or HSL inhibitor (70mg/kg once daily) for 11 days. Eight week-old 1038 
DBA2/J and C57BL6/J male mice (Charles River) were fed high fat diet (60% kcal fat, 1039 
D12492 from Research Diets) for 6 weeks before sacrifice. Mice were housed and 1040 
manipulated according to Inserm guidelines and European Directive 2010/63/UE in the local 1041 
animal care facility (agreements A 31 555 04 and C 31 555 07). Protocols were approved by 1042 
the French Ministry of Research following review by local ethical committee (CEEA122). 1043 
In studies on ChREBP null mice, 10 to 12 week-old male and female Mlxipl global knockout 1044 
mice 56 and wild-type littermates were maintained in a 12-h light/dark cycle with water and 1045 
chow diet (65% carbohydrate, 11% fat, and 24% protein). For fasting-refeeding experiment, 1046 
mice were either fasted for 24h (fasted group) or refed for 18h on chow diet and had access to 1047 
drinking water with 20% glucose, following a 24h fast (Refed group). Mice were housed and 1048 
manipulated according to Inserm guidelines and European Directive 2010/63/UE in the local 1049 
animal care facility (agreement A751320). Protocols were approved by the French Ministry of 1050 
Research following review by local ethical committee (CEEA34). 1051 
Mice homozygous for a deletion in Elovl6 and their wild-type littermates were phenotyped on 1052 
a C56BL6/J background 57. The research has been regulated under the Animals (Scientific 1053 
Procedures) Act 1986 Amendment Regulations 2012 following ethical review by the 1054 
University of Cambridge Animal Welfare and Ethical Review Body (AWERB). 1055 
Gene and protein expression analyses. See Supplementary Methods. 1056 
Measurement of fasting glucose and insulin. See Supplementary Methods. 1057 
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Glucose and insulin tolerance tests and insulin bolus injection. See Supplementary Methods. 1058 
Euglycemic-hyperinsulinemic clamp. See Supplementary Methods. 1059 
Human research. Nature of the groups was blinded to the investigator performing gene 1060 
expression experiments. 1061 
Women with differing obese and metabolic status. Participating women (lean group mean age 1062 
37 ± 16 years; obese with metabolic syndrome group mean age, 49 ± 11 years) were 1063 
scheduled to have abdominal surgery (laparoscopic or laparotomic cholecystectomy and 1064 
gastric banding) 58. During the surgical procedure, samples of visceral adipose tissue were 1065 
obtained by surgical excision. Euglycemic hyperinsulinemic clamp was performed at rest 1066 
after an overnight fast. Each subject gave written informed consent and the study was 1067 
approved by the Ethics Committee of the Third Faculty of Medicine, Charles University, 1068 
Prague. 1069 
Hyperglycemic hyperinsulinemic clamp. The 8 participating men were 23 ± 3 years-old 1070 
(BMI, 23 ± 2 kg/m2). The hyperglycemic hyperinsulinemic clamp was a modification of the 1071 
hyperglycemic method used by Del Prato et al. combined with the original hyperinsulinemic 1072 
clamp described by Defronzo 59,60. For hyperglycemia, the objective was to increase plasma 1073 
glucose 5.5 mmol/l above fasting level by infusing 20% dextrose in two phases: 1) bolus dose 1074 
to increase glycemia to the desired target and 2) continuous infusion dose adjusted every 5–10 1075 
min according to measured plasma glucose to maintain glycemia at the desired target. To 1076 
obtain hyperinsulinemia, insulin was co-infused at the rate of 75 mU/m2·min for 180 min. The 1077 
study was approved by the Ethics Committee of University of Montreal. The volunteers gave 1078 
their written consent after being informed of the nature, purpose, and possible risks of the 1079 
study. 1080 
Morbidly obese subjects undergoing bariatric surgery. This cohort has in part been described 1081 
before 61. In brief, 14 obese women (BMI>35 kg/m2; age, 48 ± 9 years) referred to the 1082 
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hospital for gastric by-pass surgery (Roux-en-Y) were investigated before surgery and 2 years 1083 
post-operatively. According to self-report, body weight had been stable (± 2 kg) for at least 3 1084 
months prior to both investigations. The study was approved by the regional ethics board in 1085 
Stockholm and registered at clinicaltrials.gov as NCT01785134. Subjects were randomized to 1086 
omentectomy or not and this was blinded to investigators and patients. Procedure was 1087 
explained in detail to each women and written informed consent was obtained. 1088 
Gene expression analysis. See Supplementary Methods. 1089 
 1090 
Statistical analysis. Results from biological replicates were expressed as mean ± SEM. 1091 
Statistical analyses were performed using GraphPad Prism (GraphPad Software v.5.0). 1092 
D’Agostino and Pearson omnibus normality test was used to test normality. Fischer test was 1093 
used to test for equality of variances. Data were Log transformed when appropriate to reach 1094 
normality and uniform distribution. Statistical tests were two-sided. Paired or unpaired 1095 
Student's t tests, Wilcoxon’s test and, Mann and Whitney’s test were performed to compare 1096 
two conditions. Paired or unpaired one-way ANOVA and Friedman’s tests were performed 1097 
and followed respectively by Bonferroni’s and Dunn’s post hoc tests to determine differences 1098 
between several groups. Paired or unpaired two-way ANOVA with Bonferroni’s post hoc 1099 
tests were used to compare two variables. Linear regression was used to test association 1100 
between two variables. 1101 
 1102 
Data availability statement. The data that support the plots within this paper and other 1103 
findings of this study are available from the corresponding author upon reasonable request.  1104 
  1105 
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